Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate
Benzinga Newsdesk 8 months ago
EarningsEarnings MissesNews
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 60 percent decrease over losses of $(0.10) per share
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 60 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $1.295 million which missed the analyst consensus estimate of $1.938 million by 33.19 percent. This is a 85.94 percent decrease over sales of $9.211 million the same period last year.